Published in Cancer Immunol Immunother on May 05, 2006
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology (2013) 1.35
Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics (2009) 0.98
Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. Br J Cancer (2013) 0.88
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem (2013) 0.86
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother (2008) 0.81
Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells. Cancer Immunol Immunother (2010) 0.81
Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology (2013) 0.81
Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2016) 0.75
Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine. Onco Targets Ther (2016) 0.75
How to detour Treg cells in T cell-based antitumor immune therapy. Onco Targets Ther (2013) 0.75
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 3.75
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Urinary diversion. Urology (2007) 2.65
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol (2002) 1.92
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood (2009) 1.79
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord (2009) 1.69
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68
Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol (2004) 1.63
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60
More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56
Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol (2013) 1.52
Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51
The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol (2006) 1.45
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41
Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2006) 1.40
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (2008) 1.40
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res (2002) 1.23
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood (2012) 1.23
Towards patient-specific tumor antigen selection for vaccination. Immunol Rev (2002) 1.22
Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol (2008) 1.20
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun (2013) 1.18
Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood (2011) 1.18
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol (2004) 1.13
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med (2013) 1.11
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J (2007) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res (2011) 1.10